Virginia is currently home to 1836 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Richmond, Charlottesville, Norfolk and Fairfax. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Phase 1 Study of BHV-1530 in Advanced Solid Tumors
NCT06874335
Recruiting
This is a Phase 1, first in human (FIH), open-label, multicenter study of BHV-1530 in adult participants with advanced or metastatic solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: Site-102, Fairfax, Virginia
Conditions: Solid Tumor
Register for Updates
Trial Readiness and Endpoint Assessment in Pediatric Myotonic Dystrophy Extension
NCT06747884
Recruiting
This is a natural history study to improve the types of assessments and biological samples that will be used in clinical drug trials in both congenital myotonic dystrophy and childhood myotonic dystrophy.
Gender:
ALL
Ages:
Between 3 years and 17 years
Trial Updated:
06/06/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Congenital Myotonic Dystrophy, Childhood Myotonic Dystrophy, Myotonic Dystrophy
Register for Updates
Advancing Water Security: A Community Participatory School-Based Hydration Intervention
NCT06714929
Recruiting
The goal of this study is to determine the effectiveness and sustainability of a community-participatory hydration intervention over 3 years within a district that has newly installed hydration stations and is operating under a policy designed to enhance heathy hydration practices and promote equitable access to drinking water.
Gender:
ALL
Ages:
4 years and above
Trial Updated:
06/06/2025
Locations: Children's Hospital of Richmond at VCU Healthy Lifestyles Center, Henrico, Virginia
Conditions: Dental Caries, Obesity Prevention
Register for Updates
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
NCT06627647
Recruiting
The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatment of patients with non-squamous mNSCLC whose tumors express PD-L1.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: Research Site, Fairfax, Virginia
Conditions: Non-squamous Non-small Cell Lung Cancer
Register for Updates
Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
NCT06596694
Recruiting
Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are advanced (the cancer has spread to other parts of the body). The goals of this study are to learn: * About the safety and how well people tolerate of patritumab deruxtecan * How many people have the cancer respond (get smaller or go away) to treatment
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: Oncology and Hematology Associates of Southwest Virginia (BRCC) ( Site 1207), Roanoke, Virginia
Conditions: Gastrointestinal Cancer
Register for Updates
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK
NCT06556368
Recruiting
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants with Neovascular (Wet) Age-related Macular Degeneration (wAMD)
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/06/2025
Locations: Piedmont Eye Center, Lynchburg, Virginia
Conditions: Wet Age-related Macular Degeneration
Register for Updates
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
NCT06541704
Recruiting
This study is researching experimental (study) drugs called pozelimab and cemdisiran. The study is focused on participants who have geographic atrophy (GA) caused by age-related macular degeneration (AMD). Geographic atrophy is a medical term that refers to later-stage cases of AMD which is an eye condition affecting central vision (what one sees straight ahead). The purpose of this study is to evaluate the progression rate of Geographic Atrophy in eyes of patients treated with cemdisiran alone... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/06/2025
Locations: Piedmont Eye Center, Lynchburg, Virginia
Conditions: Age-related Macular Degeneration (AMD), Geographic Atrophy (GA)
Register for Updates
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
NCT06492616
Recruiting
The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: Inova Schar Cancer Institute, Fairfax, Virginia
Conditions: Breast Cancer
Register for Updates
A Study to Learn More About How Well BAY 2927088 Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
NCT06452277
Recruiting
Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor receptor 2 (HER2) mutations. Advanced NSCLC is a group of lung cancers that have spread to nearby tissues or to other parts of the body or that are unlikely to be cured or controlled with currently available treatments. HER2 is a protein that helps cells to grow and divide. A damage (also called mutation) to the building... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Advanced Non-small Cell Lung Cancer, HER2 Mutation
Register for Updates
Transorb™ Self-Gripping Resorbable Mesh in High-risk Subjects Undergoing Open Repair of Ventral Hernia
NCT06449378
Recruiting
The purpose of RECOVER is to evaluate the performance and safety of Transorb™ self-gripping resorbable mesh in high-risk subjects (at least one risk factor impairing wound healing) when used for reinforcement of abdominal wall soft tissues in procedures involving open extraperitoneal ventral hernia repair, in clean (US); and clean and clean-contaminated (Europe) surgical fields (Centers for Disease Control and Prevention (CDC) Classification I and II. Data from this study will primarily be used... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: TPMG General Surgery and Hernia Center, Newport News, Virginia
Conditions: Hernia, Hernia, Ventral, Hernia, Abdominal, Hernia Abdominal Wall
Register for Updates
A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors
NCT06384807
Recruiting
This is a Phase 1/2, first in human (FIH), open-label, multicenter study of BHV-1510 monotherapy and in Combination with Cemiplimab in participants with previously treated, advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: Site-102, Fairfax, Virginia
Conditions: Solid Tumor
Register for Updates
A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis
NCT06360094
Recruiting
Adults 40 years of age and older with idiopathic pulmonary fibrosis (IPF) or 18 years and older with progressive pulmonary fibrosis (PPF) can participate in this study. Only people who have a chronic cough can take part. The purpose of this study is to find out how well BI 1839100 helps reduce coughing in people with IPF or PPF. Participants who have IPF are put into 4 groups by chance. Participants in 3 groups get different doses of BI 1839100. Participants in 1 group get placebo. Placebo look... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: Pulmonary Associates of Richmond, Inc., Richmond, Virginia
Conditions: Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Register for Updates